Clinical Report: Evaluation of Tislelizumab with Gemcitabine for Urothelial Carcinoma

Overview

This phase 2 study evaluates the efficacy and safety of tislelizumab combined with gemcitabine in patients with locally advanced or metastatic urothelial carcinoma who are unfit for cisplatin. The results indicate a median progression-free survival of 13.9 months and a median overall survival of 23.3 months, with an overall response rate of 46.7%.

Background

Locally advanced or metastatic urothelial carcinoma (la/mUC) poses significant treatment challenges, particularly for patients ineligible for cisplatin due to renal impairment or other comorbidities. The introduction of immune checkpoint inhibitors (ICIs) has changed the treatment landscape, but many patients still lack effective options. This study aims to address the unmet need for effective therapies in this patient population.

Data Highlights

Key Findings

• The combination of tislelizumab and gemcitabine showed a median progression-free survival of 13.9 months.
• The median overall survival was reported at 23.3 months.
• The confirmed overall response rate was 46.7% among the enrolled patients.
• The disease control rate reached 76.7%.
• Common treatment-related adverse events included hematological toxicities, particularly leukopenia and neutropenia.
• There was a noted difference in response rates based on tumor-associated TLS status, though not statistically significant.

Clinical Implications

The findings suggest that tislelizumab combined with gemcitabine may be a viable first-line treatment option for patients with la/mUC who cannot tolerate cisplatin. Clinicians should consider this combination in treatment planning, particularly for patients with limited options due to comorbidities.

Conclusion

The study indicates that tislelizumab and gemcitabine may offer a promising therapeutic strategy for cisplatin-ineligible patients with la/mUC, warranting further investigation in larger trials.

Related Resources & Content

1. FDA, FDA, 2023 -- FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer
2. FDA, FDA, 2024 -- FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
3. The ASCO Post — RATIONALE 208: ‘Durable Clinical Activity’ Reported With Tislelizumab in Advanced Liver Cancer
4. The ASCO Post — Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
5. the asco post — Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
6. The ASCO Post — Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
7. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer | FDA
8. FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma | FDA
9. Drug Trials Snapshots: TEVIMBRA | FDA